Claudia Trenkwalder1, Fabrizio Stocchi2, Werner Poewe3, Nalina Dronamraju4, Chris Kenney4, Amy Shah4, Florian von Raison5, Ana Graf5. 1. Paracelsus-Elena Klinik, Kassel 34128, Germany; Department of Neurosurgery, University Medical Center, Goettingen, Germany. 2. IRCCS San Raffaele Pisana, Rome, Italy. 3. Department of Neurology, Medical University, Innsbruck, Austria. 4. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. 5. Novartis Pharma AG, Basel, Switzerland.
Abstract
BACKGROUND: Two phase 2 randomized, double-blind studies were designed to evaluate efficacy and safety of immediate-release (study 1) and modified-release (study 2) mavoglurant formulations in PD l-dopa-induced dyskinesia. METHODS: Patients were randomized to mavoglurant 100-mg or placebo (4:3) groups (study 1) and mavoglurant 200-mg, mavoglurant 150-mg, or placebo (2:1:1) groups (study 2). Primary outcome was antidyskinetic efficacy, as measured by change from baseline to week 12 in modified Abnormal Involuntary Movement Scale total score. RESULTS: Differences in least-squares mean (standard error) change in modified Abnormal Involuntary Movement Scale total score in week 12 did not reach statistical significance in either study (study 1: mavoglurant 100 mg twice a day versus placebo, 1.7 [1.31]; study 2: mavoglurant 150 mg twice a day (-1.3 [1.16]) and 200 mg twice a day (-0.2 [1.03]) versus placebo). Adverse events incidence was higher with mavoglurant than with placebo. CONCLUSIONS: Both studies failed to meet the primary objective of demonstrating improvement of dyskinesia with mavoglurant treatment.
RCT Entities:
BACKGROUND: Two phase 2 randomized, double-blind studies were designed to evaluate efficacy and safety of immediate-release (study 1) and modified-release (study 2) mavoglurant formulations in PD l-dopa-induced dyskinesia. METHODS:Patients were randomized to mavoglurant 100-mg or placebo (4:3) groups (study 1) and mavoglurant 200-mg, mavoglurant 150-mg, or placebo (2:1:1) groups (study 2). Primary outcome was antidyskinetic efficacy, as measured by change from baseline to week 12 in modified Abnormal Involuntary Movement Scale total score. RESULTS: Differences in least-squares mean (standard error) change in modified Abnormal Involuntary Movement Scale total score in week 12 did not reach statistical significance in either study (study 1: mavoglurant 100 mg twice a day versus placebo, 1.7 [1.31]; study 2: mavoglurant 150 mg twice a day (-1.3 [1.16]) and 200 mg twice a day (-0.2 [1.03]) versus placebo). Adverse events incidence was higher with mavoglurant than with placebo. CONCLUSIONS: Both studies failed to meet the primary objective of demonstrating improvement of dyskinesia with mavoglurant treatment.
Authors: Angela Arsova; Thor C Møller; Line Vedel; Jakob Lerche Hansen; Simon R Foster; Karen J Gregory; Hans Bräuner-Osborne Journal: Mol Pharmacol Date: 2020-05-01 Impact factor: 4.436
Authors: Andrew S Felts; Alice L Rodriguez; Ryan D Morrison; Anna L Blobaum; Frank W Byers; J Scott Daniels; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley; Kyle A Emmitte Journal: Bioorg Med Chem Lett Date: 2018-04-22 Impact factor: 2.823
Authors: Andrew S Felts; Alice L Rodriguez; Ryan D Morrison; Katrina A Bollinger; Daryl F Venable; Anna L Blobaum; Frank W Byers; Analisa Thompson Gray; J Scott Daniels; Colleen M Niswender; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley; Kyle A Emmitte Journal: Bioorg Med Chem Lett Date: 2017-09-20 Impact factor: 2.823
Authors: Andrew S Felts; Katrina A Bollinger; Christopher J Brassard; Alice L Rodriguez; Ryan D Morrison; J Scott Daniels; Anna L Blobaum; Colleen M Niswender; Carrie K Jones; P Jeffrey Conn; Kyle A Emmitte; Craig W Lindsley Journal: Bioorg Med Chem Lett Date: 2018-11-10 Impact factor: 2.823
Authors: Andrew S Felts; Alice L Rodriguez; Anna L Blobaum; Ryan D Morrison; Brittney S Bates; Analisa Thompson Gray; Jerri M Rook; Mohammed N Tantawy; Frank W Byers; Sichen Chang; Daryl F Venable; Vincent B Luscombe; Gilles D Tamagnan; Colleen M Niswender; J Scott Daniels; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley; Kyle A Emmitte Journal: J Med Chem Date: 2017-05-31 Impact factor: 7.446